Who owns enGene Therapeutics Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of ENGN from SEC Form 13F filings across 56 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 56 institutions disclosed 38.5M shares of enGene Therapeutics Inc. worth $66.6M — about 55.2% of shares outstanding; the largest disclosed holder is BML Capital Management, LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
56
13F holders
$66.6M
value, 2026 filers
55.2%
of shares outstanding (38.5M sh)
55
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of ENGN's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BML Capital Management, LLCNEW | 6.7M | $11.5M | 6.6% | 9.6% | new |
| 2 | Siren, L.L.C.NEW | 6.3M | $10.8M | 0.2% | 9% | new |
| 3 | PERCEPTIVE ADVISORS LLCNEW | 4.8M | $8.3M | 0.1% | 6.9% | new |
| 4 | AMERIPRISE FINANCIAL INCNEW | 2.7M | $4.6M | 0.0% | 3.8% | new |
| 5 | Nextech Invest Ltd.NEW | 2.3M | $4.0M | 0.2% | 3.3% | new |
| 6 | ADAR1 Capital Management, LLCNEW | 2.1M | $3.6M | 0.2% | 3% | new |
| 7 | Vestal Point Capital, LPNEW | 1.7M | $2.9M | 0.1% | 2.4% | new |
| 8 | ACORN CAPITAL ADVISORS, LLCNEW | 1.3M | $2.2M | 0.6% | 1.8% | new |
| 9 | Peapod Lane Capital LLCNEW | 1.1M | $1.9M | 1.3% | 1.6% | new |
| 10 | Balyasny Asset Management L.P.NEW | 1.0M | $1.7M | 0.0% | 1.4% | new |
| 11 | MILLENNIUM MANAGEMENT LLCNEW | 966,627 | $1.7M | 0.0% | 1.4% | new |
| 12 | RENAISSANCE TECHNOLOGIES LLCNEW | 829,700 | $1.4M | 0.0% | 1.2% | new |
| 13 | CITADEL ADVISORS LLCNEW | 717,686 | $1.2M | 0.0% | 1% | new |
| 14 | Affinity Asset Advisors, LLCNEW | 600,000 | $1.0M | 0.0% | 0.9% | new |
| 15 | UBS Group AGNEW | 509,087 | $880,721 | 0.0% | 0.7% | new |
| 16 | Eversept Partners, LPNEW | 469,584 | $812,380 | 0.0% | 0.7% | new |
| 17 | Kynam Capital Management, LPNEW | 457,855 | $792,089 | 0.0% | 0.7% | new |
| 18 | Seven Fleet Capital Management LPNEW | 411,065 | $711,142 | 0.1% | 0.6% | new |
| 19 | JANE STREET GROUP, LLCNEW | 382,459 | $661,654 | 0.0% | 0.5% | new |
| 20 | Rangeley Capital, LLCNEW | 305,102 | $527,826 | 0.5% | 0.4% | new |
| 21 | BARCLAYS PLCNEW | 282,515 | $488,751 | 0.0% | 0.4% | new |
| 22 | KENNEDY CAPITAL MANAGEMENT LLCNEW | 268,735 | $464,912 | 0.0% | 0.4% | new |
| 23 | Woodline Partners LPNEW | 250,000 | $432,500 | 0.0% | 0.4% | new |
| 24 | Quadrature Capital LtdNEW | 239,035 | $413,531 | 0.0% | 0.3% | new |
| 25 | Squarepoint Ops LLCNEW | 215,381 | $372,609 | 0.0% | 0.3% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.